Spinal Muscular Atrophy
ICER developed a report assessing the comparative clinical effectiveness and value of onasemnogene abeparvovec (Zolgensma®, Novartis AG/AveXis) and nusinersen (Spinraza®, Biogen) for treatment of spinal muscular atrophy (SMA).
For questions, please contact Matt Seidner, Program Director, at firstname.lastname@example.org.
Omni Parker House
60 School Street
Boston, MA 02108
The New England CEPAC convened to deliberate and vote on ICER's report on treatments for SMA.